Celularity is a biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases.
We are a clinical and commercial stage biotechnology company leading the next evolution in cellular and regenerative medicine with off-the-shelf placental-derived allogeneic cell therapies and biomaterial products designed for serious unmet medical needs. The Next Evolution In Cellular Medicine.
About us. Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic...
Celularity Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using unmodified natural killer (NK) cells, genetically modified NK ...
DA:50PA:36MOZ Rank:42
Celularity Receives Healthcare Common Procedure Coding
3 days ago · Celularity Inc. (NASDAQ: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all ...
DA:41PA:83MOZ Rank:32
Celularity Receives Healthcare Common Procedure Coding …
3 days ago · Celularity Inc. (NASDAQ: CELU) is a regenerative medicine company developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all ...
Mar 21, 2024 · FLORHAM PARK, N.J., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”) a biotechnology company developing allogeneic cell therapies and advanced biomaterial products, tod... 2 months ago - GlobeNewsWire. Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023.
DA:30PA:96MOZ Rank:39
Celularity Inc. (CELU) Company Profile & Overview - Stock Analysis
6 days ago · 5.19. -0.17 (-3.17%) Mar 22, 2024, 4:30 PM EDT - Market closed. Financials. Company Description. Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies. Florham Park, New Jersey, United States. 101-250. Post-IPO Equity. Public. www.celularity.com. 3,599. Highlights. Stock Symbol NASDAQ:CELU. Acquisitions 1. Total Funding Amount. Unlock for free. Contacts 199.
DA:54PA:47MOZ Rank:50
Celularity Inc. (CELU) Company Profile & Facts - Yahoo Finance
Celularity Inc. (CELU) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.91 +0.21 (+3.68%) As of 02:05PM EDT. Market open. Summary.